Cargando…

Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization

Detalles Bibliográficos
Autores principales:	Ganzinelli, Monica, Ribeiro, Enilze, Bertoni, Ramona, Bazzola, Letizia, Andreis, Daniele, Bottini, Alberto, Giardini, Roberto, Rossi, Camillo, Damia, Giovanna, Generali, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326864/ http://dx.doi.org/10.1186/1897-4287-10-S2-A37

Ejemplares similares

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
por: Ribeiro, Enilze, et al.
Publicado: (2013)

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines
por: de Oliveira, Sarah Franco Vieira, et al.
Publicado: (2016)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications
por: Tierno, Domenico, et al.
Publicado: (2023)

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
por: Cappelletti, Maria Rosa, et al.
Publicado: (2015)

Women temporarily synchronize their menstrual cycles with the luminance and gravimetric cycles of the Moon
por: Helfrich-Förster, C., et al.
Publicado: (2021)

Continuous measurement of gut luminal pCO(2) in an animal model — a sensitive index of reduced perfusion
por: Morgan, J, et al.
Publicado: (1997)

U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint
por: Carrassa, Laura, et al.
Publicado: (2009)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis
por: Barton, Maria, et al.
Publicado: (2019)

Double and triple gene transfer in arthritis
por: Müller-Ladner, U, et al.
Publicado: (2001)

Novel lncRNAs Co-Expression Networks Identifies LINC00504 with Oncogenic Role in Luminal A Breast Cancer Cells
por: Mathias, Carolina, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Usefulness of double luminal drain with continuous high-pressure aspiration for draining mucinous discharge in abdominal sepsis: prevention of worsening of local inflammation until definitive surgery
por: Yoshihiro, M, et al.
Publicado: (2003)

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials
por: Roviello, Giandomenico, et al.
Publicado: (2016)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Brachial plexus injury - from double to triple FFMT
por: Tu, Yuan-Kun
Publicado: (2015)

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
por: Zheng, Hongping, et al.
Publicado: (2017)

Cell-cycle regulation
por: Bhalla, Needhi
Publicado: (2002)

Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events
por: Kottschade, Lisa
Publicado: (2021)

Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment
por: Rubin, Krista M., et al.
Publicado: (2020)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

WG2 Higgs Properties: Outlook and Plans
por: Barducci, Daniele
Publicado: (2022)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2015)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Evolution of gossip-based indirect reciprocity on a bipartite network
por: Giardini, Francesca, et al.
Publicado: (2016)

Demonstration of sub-luminal propagation of single-cycle terahertz pulses for particle acceleration
por: Walsh, D. A., et al.
Publicado: (2017)

Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells
por: Ozawa, Patricia Midori Murobushi, et al.
Publicado: (2018)

Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments
por: Greene, Heather R., et al.
Publicado: (2020)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
por: Generali, D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kerf3h3c3gjd5g725j6vmmo94d